Aptose Biosciences Inc (APTO) was Upgraded by ROTH Capital to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. ROTH Capital advised their investors in a research report released on Jun 13, 2016.
Many Wall Street Analysts have commented on Aptose Biosciences Inc. Shares were Reiterated by RBC Capital Mkts on Mar 30, 2016 to “Outperform” and Lowered the Price Target to $ 18 from a previous price target of $19 .
Aptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company’s group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML) myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally the Company has a preclinical small molecule program APTO-500 targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company’s large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).